Loading...
•
Sep 30, 2022
Integra LifeSciences Q3 2022 Earnings Report
Integra LifeSciences' Q3 2022 financial results were reported, with revenues decreasing slightly on a reported basis but increasing organically, and the company raising its earnings per share outlook for the full year.
Key Takeaways
Integra LifeSciences reported a slight decrease in total revenues but an increase in organic revenue for Q3 2022. GAAP EPS was $0.60, while adjusted EPS remained flat at $0.86. The company completed the sale of its traditional wound care business and raised its full-year EPS outlook.
Total revenues decreased by 0.4% on a reported basis but increased by 3.5% on an organic basis.
GAAP earnings per diluted share increased to $0.60, while adjusted earnings per diluted share remained flat at $0.86.
The sale of the non-core traditional wound care business was completed.
Full-year 2022 revenue guidance was reaffirmed at the midpoint, with a tightened range of $1,551 million to $1,563 million, and the earnings per share outlook was raised.
Forward Guidance
The Company expects Q4 2022 reported revenues in the range of $391 million to $403 million, representing reported growth of -3.5% to -0.6% and organic growth of 1.3% to 4.3%. Adjusted earnings per diluted share is expected to be in a range of $0.87 to $0.91.
Positive Outlook
- Q4 organic growth expected between 1.3% and 4.3%.
- Adjusted earnings per diluted share expected between $0.87 and $0.91.
- Full year revenue expectations reaffirmed.
- Full year adjusted EPS guidance raised.
- Company is focused on execution in achieving short- and long-term targets.
Challenges Ahead
- Q4 reported revenue growth expected between -3.5% and -0.6%.
- Macro environment headwinds.
- Continuing supply constraints.
- Potential adjustments to the CereLink reserve.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...